A molecular guide to systemic therapy in salivary gland carcinoma

Area of Science:

• Oncology
• Head and Neck Cancer Research
• Molecular Diagnostics

Background:

• Salivary gland carcinomas (SGCs) represent a rare and heterogeneous category of head and neck malignancies.
• Historically, SGCs have demonstrated limited responsiveness to conventional chemotherapy and immunotherapy, particularly in recurrent, advanced, or metastatic stages.

Purpose of the Study:

• To review the current landscape of precision therapy for salivary gland carcinomas.
• To discuss emerging molecular targets and their impact on treatment outcomes.
• To outline ongoing clinical trials and future therapeutic strategies for SGCs.

Main Methods:

• Literature review of precision therapies for SGCs.
• Analysis of identified molecular alterations (e.g., HER2, androgen receptor, Notch, NTRK, RET).
• Summary of current systemic treatment options and clinical trial data.

Main Results:

• Identification of targetable molecular alterations in SGCs, including HER2 upregulation, androgen receptor overexpression, Notch receptor activation, NTRK gene fusions, and RET alterations.
• Demonstrated improvement in treatment outcomes due to targeted therapies in recent years.
• Active clinical trials exploring novel therapeutic strategies.

Conclusions:

• Precision therapy has transformed the management of SGCs.
• Targeting specific molecular alterations offers improved outcomes for patients with advanced disease.
• Continued research and clinical trials are crucial for further advancing SGC treatment.